Supernus Pharmaceuticals, Inc. (SUPN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1161253,
    "name": "Supernus Pharmaceuticals, Inc.",
    "stock_name": "Supernus Pharmaceuticals, Inc.",
    "full_name": "Supernus Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/supernus-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "45.10",
    "chg": 0.98,
    "chgp": "2.22%",
    "dir": 1,
    "prev_price": "44.12",
    "mcapval": "2,569.27",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US8684591089",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "987.32 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/supernus-pharmaceuticals-inc-1161253-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Supernus Pharmaceuticals Hits New 52-Week High of $57.65",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-hits-new-52-week-high-of-5765-3661982",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SupernusPharmac_priceRelatedfactors_3661982.png",
        "date": "2025-10-31 16:19:40",
        "description": "Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant stock price growth over the past year, outpacing broader market indices, and maintains a solid financial position with minimal debt reliance."
      },
      {
        "title": "Supernus Pharmaceuticals Hits New 52-Week High of $55.95",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-hits-new-52-week-high-of-5595-3659164",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SupernusPharmac_priceRelatedfactors_3659164.png",
        "date": "2025-10-30 18:41:59",
        "description": "Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 55.95 on October 29, 2025, reflecting its strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year and maintains a solid financial position with low debt reliance."
      },
      {
        "title": "Supernus Pharmaceuticals Hits New 52-Week High of $53.28",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-hits-new-52-week-high-of-5328-3649271",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SupernusPharmac_priceRelatedfactors_3649271.png",
        "date": "2025-10-27 16:55:45",
        "description": "Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a notable increase in its stock price and a solid financial position characterized by a low debt-to-equity ratio."
      },
      {
        "title": "Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-supernus-pharmaceuticals-inc-overvalued-or-undervalued-3637963",
        "imagepath": "",
        "date": "2025-10-21 12:12:28",
        "description": "As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, an EV to EBITDA of 9.02, and a Price to Book Value of 1.80. In comparison, PTC Therapeutics, Inc. has a P/E ratio of 5.85 and EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a more favorable P/E of 11.40 and EV to EBITDA of 6.94, highlighting the relative overvaluation of Supernus.\n\nDespite the company's strong recent performance, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not be a sustainable investment at its current price level...."
      },
      {
        "title": "Supernus Pharmaceuticals, Inc. Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-valuation-grade-downgraded-from-very-attractive-to-expensive-3640947",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SupernusPharmac_valuationdot_3640947.png",
        "date": "2025-10-20 16:59:27",
        "description": "Supernus Pharmaceuticals, Inc. has adjusted its valuation, reflecting shifts in financial metrics within the pharmaceuticals sector. The company exhibits a P/E ratio of 29 and a return on capital employed of 13.09%. Year-to-date, its stock has outperformed the S&P 500, indicating a strong market position."
      },
      {
        "title": "Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-supernus-pharmaceuticals-inc-overvalued-or-undervalued-3634834",
        "imagepath": "",
        "date": "2025-10-20 12:29:41",
        "description": "As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, a Price to Book Value of 1.80, and an EV to EBITDA of 9.02. In comparison, peers such as PTC Therapeutics, Inc. have a significantly lower P/E of 5.85, while Harmony Biosciences Holdings, Inc. shows a more favorable valuation with a P/E of 11.40.\n\nDespite the overvaluation, Supernus has demonstrated strong recent performance, with a year-to-date return of 38.74%, significantly outpacing the S&P 500's 13.30% return in the same period. However, its longer-term returns, particularly over three and five years, lag behind the broader market, suggesting potential concerns about sustainability at its current valuation levels...."
      },
      {
        "title": "Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-supernus-pharmaceuticals-inc-overvalued-or-undervalued-3632369",
        "imagepath": "",
        "date": "2025-10-19 12:07:03",
        "description": "As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its P/E ratio of 29, which is significantly higher than its peers, such as PTC Therapeutics, Inc. with a P/E of 5.85 and Harmony Biosciences Holdings, Inc. at 11.40. Additionally, Supernus has an EV to EBITDA ratio of 9.02, which also suggests a premium compared to its industry counterparts.\n\nIn terms of performance, Supernus has shown strong returns, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, and a one-year return of 48.26% against the S&P 500's 14.08%. This outperformance may reflect investor optimism, but the high valuation ratios indicate that the stock may not be sustainable at these levels. Overall, Supernus Pharmaceuticals, Inc. is currently overvalued...."
      },
      {
        "title": "Supernus Pharmaceuticals Hits New 52-Week High of $49.66",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-hits-new-52-week-high-of-4966-3595647",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SupernusPharmac_priceRelatedfactors_3595647.png",
        "date": "2025-10-06 17:36:12",
        "description": "Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a solid financial position characterized by a low debt-to-equity ratio and a positive return on equity."
      },
      {
        "title": "Supernus Pharmaceuticals Hits New 52-Week High of $48.00",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/supernus-pharmaceuticals-hits-new-52-week-high-of-4800-3579367",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/SupernusPharmac_priceRelatedfactors_3579367.png",
        "date": "2025-09-29 14:24:56",
        "description": "Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 48.00 on September 26, 2025, reflecting strong performance in the pharmaceuticals sector with a one-year growth of 79.57%. The company, with a market cap of USD 2,569 million, shows solid financial health and minimal debt."
      }
    ],
    "total": 18,
    "sid": "1161253",
    "stock_news_url": "https://www.marketsmojo.com/news/supernus-pharmaceuticals-inc-1161253"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Supernus Pharmaceuticals Hits New 52-Week High of $57.65

2025-10-31 16:19:40

Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant stock price growth over the past year, outpacing broader market indices, and maintains a solid financial position with minimal debt reliance.

Supernus Pharmaceuticals Hits New 52-Week High of $55.95

2025-10-30 18:41:59

Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 55.95 on October 29, 2025, reflecting its strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year and maintains a solid financial position with low debt reliance.

Supernus Pharmaceuticals Hits New 52-Week High of $53.28

2025-10-27 16:55:45

Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a notable increase in its stock price and a solid financial position characterized by a low debt-to-equity ratio.

Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-21 12:12:28

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, an EV to EBITDA of 9.02, and a Price to Book Value of 1.80. In comparison, PTC Therapeutics, Inc. has a P/E ratio of 5.85 and EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a more favorable P/E of 11.40 and EV to EBITDA of 6.94, highlighting the relative overvaluation of Supernus. Despite the company's strong recent performance, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not be a sustainable investment at its current price level....

Supernus Pharmaceuticals, Inc. Experiences Valuation Adjustment Amid Strong Market Performance

2025-10-20 16:59:27

Supernus Pharmaceuticals, Inc. has adjusted its valuation, reflecting shifts in financial metrics within the pharmaceuticals sector. The company exhibits a P/E ratio of 29 and a return on capital employed of 13.09%. Year-to-date, its stock has outperformed the S&P 500, indicating a strong market position.

Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-20 12:29:41

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, a Price to Book Value of 1.80, and an EV to EBITDA of 9.02. In comparison, peers such as PTC Therapeutics, Inc. have a significantly lower P/E of 5.85, while Harmony Biosciences Holdings, Inc. shows a more favorable valuation with a P/E of 11.40. Despite the overvaluation, Supernus has demonstrated strong recent performance, with a year-to-date return of 38.74%, significantly outpacing the S&P 500's 13.30% return in the same period. However, its longer-term returns, particularly over three and five years, lag behind the broader market, suggesting potential concerns about sustainability at its current valuation levels....

Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-19 12:07:03

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its P/E ratio of 29, which is significantly higher than its peers, such as PTC Therapeutics, Inc. with a P/E of 5.85 and Harmony Biosciences Holdings, Inc. at 11.40. Additionally, Supernus has an EV to EBITDA ratio of 9.02, which also suggests a premium compared to its industry counterparts. In terms of performance, Supernus has shown strong returns, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, and a one-year return of 48.26% against the S&P 500's 14.08%. This outperformance may reflect investor optimism, but the high valuation ratios indicate that the stock may not be sustainable at these levels. Overall, Supernus Pharmaceuticals, Inc. is currently overvalued....

Supernus Pharmaceuticals Hits New 52-Week High of $49.66

2025-10-06 17:36:12

Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a solid financial position characterized by a low debt-to-equity ratio and a positive return on equity.

Supernus Pharmaceuticals Hits New 52-Week High of $48.00

2025-09-29 14:24:56

Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 48.00 on September 26, 2025, reflecting strong performance in the pharmaceuticals sector with a one-year growth of 79.57%. The company, with a market cap of USD 2,569 million, shows solid financial health and minimal debt.

View All News